Danaher Drops Business Segments to Appease Regulators

Danaher Drops Business Segments to Appease Regulators

by | Oct 28, 2019 2:20 pm | Medical Devices, Pharmaceuticals

Danaher Corporation (NYSE: DHR) is selling a number of its business segments and assets to Sartorius AG (FWB: SRT) for $750 million. The sale includes Danaher’s label-free biomolecular charaterization, chromatography hardware and resins, and microcarriers and particle validation standards businesses, which are part of its Life Sciences segment. Danaher is selling this portion of its Life Sciences segment as a step towards obtaining regulatory approval for its pending acquisition of the GE Biopharma business (NYSE: GE). These businesses generated approximately $140 million in combined revenue in 2018. GE Life Sciences announced the sale of its biopharmaceutical business for $21.4... Read More »

Sartorius AG Scores Two More Deals

by | Apr 7, 2017 3:10 pm | eHealth, Laboratories, MRI & Dialysis, Pharmaceuticals, Private Equity

Sartorius AG (FWB: SRT), a German pharmaceutical and laboratory equipment provider, has expanded with the acquisition of a medical device company and a digital health company for a combined total of $392.5 million. Sartorius operates through two divisions: bioprocess solutions and lab products & services. On March 3, 2017, Sartorius acquired privately-held Essen BioScience Inc. from SFW Capital Partners for $320 million. Essen develops and manufactures instruments, software, reagents and consumables which enable researchers to remotely image and quantify a wide variety of cellular processes over time. Through this acquisition, Sartorius significantly expands its portfolio for... Read More »